MedTrace Logo

Comparison of Ketamine and Esketamine in Patients Suffering From Fibromyalgia Syndrome.

NCT04938713 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-08-27

No results posted yet for this study

Summary

Ketamine and Esketamine intravenous perfusions can modulate chronic pain. The purpose of this study is to determine if Ketamine or Esketamine are favorable for outpatients suffering from fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DRUG

Ketamine 50 MG/ML

Intravenous Ketalar® 0,30 mg/kg in 1 hour.

DRUG

Esketamine 25 MG/ML

Intravenous Vesierra® 0,15mg/kg in 1 hour.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Liege

    collaborator OTHER

  • Centre Hospitalier Universitaire de Charleroi

    lead OTHER

Principal Investigators

  • Brice Constant, MD · Centre Universitaire de Charleroi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-05-01
Completion
2022-09-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04938713 on ClinicalTrials.gov